Healius shares plunge after FY25 revenue, EBIT missed consensus forecasts
Make us a preferred source
Make us a preferred source on Google
More news: Healius shares sank in afternoon trade after the healthcare services provider reported lower than expected revenue and EBIT.
Healius shares at 1:31pm AEST had slipped 15.2% to 69 cents each.
RBC Capital Markets analyst Craig Wong-Pan considers the FY25 numbers “as coming in weaker than consensus expectations but the FY26 outlook to be broadly in line with consensus forecasts”.
Wong-Pan highlighted that the $1.35 billion revenue figure was below the market consensus estimate of $1.37 billion, according to Visible Alpha, and the EBIT loss of $527 million missed the expected $311 million gain.
Healius posts $151m loss amid revenue lift
The news: Healthcare services provider Healius has reported a $151.2 million loss after tax, a 77% smaller loss than the $645.8 million suffered last year as underlying earnings lifted.
The numbers: The result missed consensus forecasts of a $185.53 million profit, according to Visible Alpha data.
Revenue grew by 5.7% from $1.27 billion to $1.34 billion, behind the market consensus estimate of $1.37 billion.
The company declared no final full-year dividend, after scrapping last year's payout.
The context: Pathology revenue growth in the second half of FY25 was attributable to a changing revenue mix due to growth in specialist revenues in areas such as genomics, veterinary pathology and clinical trials, which pushed the average fee higher.
Throughout the year, GP attendances grew 2.1% and specialist attendances rose by 2.7%. The company said it remains focused on "developing the specialist referrer segment targeting haematology and genomics, which generate higher value referrals".
The Agilex Biolabs business meanwhile took a revenue hit as contracts were delayed and cancelled due to "prolonged uncertainty and volatility in global health policies, tariffs and funding of biotech and pharmaceutical research", the company said. Healius also sold the Lumus Imaging business on 1 May 2025.
The sources: ASX, RBC Capital Markets research
